March 17, 2021
Otsuka Pharmaceutical said on March 16 that it has obtained exclusive Japan rights for New York-based Perception Neuroscience’s lead compound PCN-101 (R-ketamine), a potential treatment for depression, in a bid to boost its CNS portfolio. The two companies struck a...read more